

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/09		A1	(11) International Publication Number: WO 97/00693
			(43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/AU96/00370		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 20 June 1996 (20.06.96)			
(30) Priority Data: PN 3667 20 June 1995 (20.06.95)		AU	
(71) Applicant (<i>for all designated States except US</i>): PEPTIDE TECHNOLOGY LIMITED [AU/AU]; 4-10 Inman Road, Dee Why, NSW 2099 (AU).		Published <i>With international search report.</i>	
(72) Inventors; and			
(73) Inventors/Applicants (<i>for US only</i>): WALSH, John, Desmond [NZ/AU]; 5 Stigess Avenue, Curl Curl, NSW 2096 (AU). TRIGG, Timothy, Elliot [AU/AU]; 8 Yosefa Avenue, Warrawee, NSW 2074 (AU).			
(74) Agent: F.B. RICE & CO.; 28A Montague Street, Balmain, NSW 2041 (AU).			
(54) Title: NOVEL FORMULATION FOR PEPTIDE RELEASE			
(57) Abstract			
A pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, <i>in vitro</i> , it releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37 °C at a rate of about 2-80 µg/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment, particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL FORMULATION FOR PEPTIDE RELEASE

The present invention relates to pharmaceutical and veterinary formulations for the sustained release of deslorelin which is an agonist of the peptide gonadotropin releasing hormone (GnRH). Uses of the formulations include prevention of reproductive function, particularly in dogs and cats, and treatment, particularly in humans, of prostate and breast cancer and other diseases or conditions where suppression of testosterone or estradiol levels is beneficial.

Uncontrolled reproduction in domestic pets is a world wide problem. In less developed countries, reproduction of domestic cats and dogs is relatively uncontrolled. Sporadic programs of work exist aimed at controlling reproduction in these animals by surgical castration. In the more developed countries, reproduction is controlled more by ovarioectomy in females and in some cases, by orchidectomy in males, or by physically locking away animals to prevent mating.

Surgical techniques, no matter how minor, carry some risk. Many pet owners are also loathe to have their animal surgically modified and will tolerate the problems of uncontrolled reproduction and associated behaviour. To remove the ability to reproduce from domestic pets without the use of surgery and without resorting to lengthy kennelling procedures has been an objective of the small animal research industry for some years. Drugs which are currently available for this process, are steroid-based drugs. They produce unpleasant side effects, particularly after lengthy use, and they are not widely used.

The peptide gonadotrophin releasing hormone (GnRH) has been the subject of intensive research for many years. It is a hypothalamic decapeptide which is synthesised and stored in neurosecretory cells of the medial basal hypothalamus. The releasing hormone is released in a pulsatile manner into the hypophysial portal circulation and is transported to the anterior pituitary. Here, it regulates the secretion of the gonadotrophins, leuteinising hormone (LH) and follicle stimulating hormone (FSH), into the systemic circulation. Thus, GnRH is a humoral link between the neural and endocrine components of reproductive function (for review see Conn PM (ed) 1996 Gonadotropin-releasing hormone Endocrine Review 2:1). GnRH binds to a single class of receptors on gonadotrope cells. Prolonged exposure

of these cells to the GnRH results in loss of responsiveness to the hormone, through receptor alteration (reviewed in Hazum E and Conn PM (1988) Endocrine Review 9: 379-866). The outcome of down-regulation of responsiveness to GnRH is suppression of circulating levels of gonadotropins and sex hormones. This has the consequence of suppressing reproductive function and other processes affected by sex hormone levels.

For many years, researchers have tried to develop a commercial vaccine, based on forming antibodies to GnRH, to cut this hormone axis and hence act as a contraceptive. The present applicants have commercialised such a vaccine; however, the developed technology is not suitable for contraception in pets. This lack of suitability is due to the biological variation of response in individual pets to a vaccine and the lack of predictability of the length of effect of the vaccine.

It is generally accepted in the marketplace that for a pet contraceptive to be successful, it would be preferably efficacious in all treated animals and its length of response time would be predictable. This response should preferably either be for six or twelve months. Reversibility of the effect would be an additional desirable benefit.

In 1987, Brian Vickery from Louisiana (Vickery, B.H. and Nestor, J.J. (1987) In LHRH and its Analogues, Part 2, p517-543), demonstrated that overdosing dogs/bitches with the superagonist of GnRH, nafarelin, shut down reproductive function for a variable period of three to eighteen months. The difficulties facing product development in this area have been:

- (i) to have available a source of GnRH, or an agonist, at a cost effective price; and
- (ii) to have a cost-effective delivery system for a peptide which releases at a controlled rate over six to twelve months, at a rate and dose that will shut down animals predictably and reliably for six or twelve months.

The present applicants have developed a formulation comprising deslorelin as the active agent which, when administered to animals, prevents reproductive function over an extended and predictable period of time. The formulation also allows the restoration of reproductive function following termination of administration. Whilst the formulation is particularly described in relation to dogs, it is believed that the formulation will be useful in other animals such as humans.

In addition, the use of GnRH analogues, including deslorelin, for the suppression of hormone levels in humans is well documented. Van Leusden H.A.I.M. (*Gynecol Endocrinol* 8 (1994) 215-222) has reviewed the use of a variety of GnRH agonist peptides for suppression of estradiol levels in female patients and use for the treatment of endometriosis and leiomyoma. From a survey of a large body of published work, these authors concluded that many GnRH analogues, including deslorelin, were effective in suppressing estradiol levels and hence in treating these sex hormone-accelerated conditions provided that the peptide was delivered so as to maintain a constant minimum blood level. The prerequisite for a peptide to be active was the ability to disturb the pulsatile release of endogenous GnRH. This required a constant minimum plasma level (this level was not defined). They suggested that a mode of delivery was more important than minor differences in potency between different GnRH analogues. These authors also concluded that in a suppressed pituitary, the dose of GnRH analogue needed to maintain suppression gradually decreased with the duration of treatment (also explored in Sandow J and Donnez T (1990) in Brosens I, Jacobs HS and Rennebaum B (eds) LHRH analogues in Gynaecology pp 17-31 Camforth: Parthenon Publishing).

Similarly, the use of GnRH agonists including deslorelin, in the treatment of sex hormone dependent tumours, including breast cancer and prostate cancer, has been described. Redding *et al*, (1984) *Proc Natl Acad Sci USA* 81 5845-5848 described the use of a GnRH analogue [D Trp⁶] LH-RH for suppression of prostate cancer in rats and demonstrated that a microencapsulated form of the peptide, delivering a controlled dose over a 30 day period was more effective in suppressing serum testosterone levels and prostate tumour weight than daily subcutaneous administration of equivalent or double doses of the free peptide. The value of this analogue in human prostate cancer patients to suppress testosterone levels and show tumour progression has been demonstrated by Parmar H *et al* (1985) *The Lancet* Nov 30, 1201-1205. This one month depot injection of a GnRH agonist has now been registered for use and tested and used widely in the treatment of breast, ovarian and prostate cancer, endometriosis, myoma and in precocious puberty in children, as have other GnRH agonists. (Nelson JR and Corson SL (1993) *Fertil Steril* 59: 441-3; Paul D, Conte FA, Grumbach, MM and Kaplan SL (1995) *J Clin Endocrin Metab* 80: 546-551).

A three month depot preparation of a GnRH agonist has also been described (Okada H, Doken Y, Ogawa Y and Toguchi H (1994) Pharm Res (US) 11: 1199-1203.). Linear drug release from the injected microspheres was obtained with persistent suppression of serum LH, FSH (rats) and 5 testosterone (rats and dogs) for over 16 weeks. Doses of GnRH analogues used to suppress sex hormone levels in males and females are the same (e.g. Plosker, G.L. and Brogden, R.V. (1994) Drugs Vol. 48, pages 930-967). Thus, the demonstration of suppression of sex hormone levels in one sex is predictive of similar suppression in the other sex.

10 Accordingly, the abovementioned deslorelin formulation developed by the present applicants, is also useful for treating a range of hormone dependent diseases and conditions in animals (including humans) such as those mentioned above. The formulation offers an improved treatment for these hormone dependent diseases and conditions, by continuing to deliver 15 the GnRH analogue over a period of 12 months or more, thus reducing the need for frequent subcutaneous injections or implant insertions.

20 Thus, in a first aspect, the present invention provides a pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, *in vitro*, it releases deslorelin into phosphate buffered saline, as hereinafter described, at 37°C at 25 a rate of about 2-80 µg/day for at least 200 days but preferably for at least 300 days.

In a second aspect the present invention consists in a method of preventing reproductive function in animals for at least 3 months, the 30 method comprising administering to the animal the formulation of the first aspect of the invention.

In a third aspect, the present invention consists in a method of treating a disease or condition for which suppression of sex hormone levels is beneficial in an animal, the method comprising administering to the animal the formulation of the first aspect of the invention.

35 In a preferred embodiment of the present invention the formulation comprises about 2-10%(w/w) deslorelin (on an active basis), about 0.5-2.5%(w/w) lecithin and about 85-97.5%(w/w) stearin.

More preferably, the formulation comprises about 5-10% (w/w) 40 deslorelin (on an active basis), about 0.5-1.5% (w/w) lecithin and about 89-94% (w/w) stearin.

Particularly preferred formulations are;

- (I) 94% (w/w) stearin, 5% (w/w) deslorelin (on an active basis) and 1% (w/w) lecithin, and
(II) 93% (w/w) stearin, 5% (w/w) deslorelin (on an active basis) and 2% (w/w) lecithin.

In a still further preferred embodiment of the present invention the formulation is for administration to humans, or dogs and/or cats.

The formulation will typically exist in the form of rods which have been extruded. The rods will then be cut into predetermined lengths for implantation in the animal. As will be readily appreciated the length of rod will determine the rate and dose of deslorelin. As opposed to implanting longer rods more than one rod can be implanted in each animal.

The disease or condition referred to in the method of the third aspect of the invention may be any disease or condition wherein reduction of sex hormone (testosterone or estradiol) levels over a prolonged period is beneficial. Examples include prostate cancer, ovarian and breast cancer, benign hormone-dependent disorders such as endometriosis, myoma and premenstrual tension, and precocious puberty in children.

Deslorelin is described in U.S. Patent No. 4218439. Deslorelin has the formula [6-D-tryptophan-9-(N-ethyl-L prolinamide)-10-deglicinamide] or P Glutamine-Histidine-Tryptophan-Serine-Tyrosine-D Tryptophan-Leucine-Arginine-Proline-ethylamide.

Stearin is partially hydrogenated palm oil. Its principle fatty acids are C16:0(45%) and C18:0(53%). Melting point is about 55°C.

Lecithin is phosphatidylcholine. It is a mixture of diglycerides of stearic, palmitic and oleic acids linked to the choline ester of phosphoric acid. Both stearin and lecithin are found in plants and animals.

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting examples and accompanying figures.

Brief description of the figures

Figure 1: Provides a graph showing the average daily *in vitro* release profile from three 60mg rods of formulation I, demonstrating an initial rapid release of the agent and then continued release extending over a prolonged period.

Figure 2: Provides a graph showing the cumulative *in vitro* release profile from three 60mg rods of formulation I, demonstrating the reproducible release observed, extending for at least 250 days.

5 Figure 3: Provides graphical results of normal plasma testosterone levels in a control dog.

Figures 4-7: Show:-

- (i) the effect of deslorelin release from formulation II on down-regulating pituitary function, thereby lowering testosterone levels to zero;
- 10 (ii) the length of the effect; and
- (iii) the reversibility of the effect.

15 Figure 8: Provides graphical results of plasma testosterone levels from two dogs implanted with rods of the deslorelin formulation. Reduction in the plasma testosterone levels after 13 days indicates contraception.

Figures 9 and 10: Provides graphical results of testicular size data from dogs implanted with the deslorelin formulation up to eight months post implantation. Testicular atrophy is seen in response to pituitary down-regulation.

20 Figure 11: Provide graphical results of testicular size data from a controlled dog, up to nine weeks post implantation with a placebo (i.e. identical formulation II less deslorelin).

25 Figure 12 and 13: Provides graphical results of plasma testosterone levels from dogs implanted with the deslorelin formulation. These dogs were euthanased after it was observed that the formulation was active, in order to collect tissues.

EXAMPLE 1: Dog contraceptive formulation I

A formulation comprising 94% stearin, 5% deslorelin (on an active basis) and 1% lecithin was evaluated in dogs. This formulation was produced as follows:

30 Stearin (supplied as free flowing beads of 1mm or less in diameter made by Vandenberg Foods) and lecithin (supplied as a deep brown viscous syrup from R P Schearer) were hand mixed using a spatula in a small beaker. The deslorelin was then added and thoroughly mixed into the excipients.

35 The mixed material was transferred to the barrel of a ram extruder that has a 1mm nozzle attached and is equilibrated to 55°C. The ram extrusion

pressure is 40psi. The ram was attached and pressure applied until the product began to extrude. At this point the pressure was backed off and the product allowed to reach 55°C. The product was then extruded - 3g over a 30 second period. The resulting exudate was allowed to cool and then
5 broken up and re-extruded through a 1mm nozzle. This step was included to ensure uniformity of content throughout the matrix. The 1mm nozzle was then replaced with a 2.3mm diameter nozzle. The same product temperature equilibration procedure was conducted prior to extrusion. The product was then extruded and after cooling the long rods produced could be
10 sectioned into lengths of the required weight.

The rods produced were implanted into male dogs using standard techniques. Results obtained demonstrated that the release of deslorelin from the rods *in vitro* followed a reproducible path and continued for up to 250 days. In the dogs a continued decline in testicular size was seen for at
15 least 5 months and suppression of plasma testosterone levels for at least 4 months were observed.

Figures 1 and 2 provide results of *in vitro* deslorelin release with 60mg rods. The assay involved immersing the rod into a container with 1ml of phosphate buffered saline (prepared as described below) which is placed in a reciprocating water bath at 37°C. The saline is replaced daily and the withdrawn saline assayed for deslorelin with HPLC.
20

Phosphate buffered saline (PBS - pH 7.3) referred to herein, is prepared by dissolving 8.00g of sodium chloride, 1.00g di-sodium hydrogen phosphate anhydrous, 0.40g sodium dihydrogen phosphate dihydrate (0.31g if anhydrous), and 0.05g sodium azide in 1 litre of deionised water.
25

EXAMPLE 2: Dog contraceptive formulation II

A formulation comprising 93% stearin, 5% deslorelin (on an active level) and 2% lecithin was evaluated in dogs. This formulation was
30 produced as follows:

Stearin beads (ADMUL PO 58 from Quest International Australasia Limited) and lecithin (Topcithin 300, Bronson & Jacobs, Australia) were hand mixed using a spatula in a small beaker. The deslorelin was then added and thoroughly mixed into the excipients. The material was
35 transferred to the barrel of a ram extruder that has a 1mm nozzle attached and is equilibrated to 55.8°C. The ram extrusion pressure is 40psi. The ram

was then attached and pressure applied until the product began to extrude. At this point the pressure was backed off and the product allowed to reach 55.8°C. The product was then extruded - 3g over a 30 second period. The resulting extrudate was allowed to cool and then broken up before re-extruding the mixed granulation through the 1mm nozzle at 58.3°C and into an injectable mould that generates a finished rod product that is 2.3mm in diameter and approximately 25mm long. The rods are then sterilised by gamma irradiation.

The rods produced were implanted into male and female dogs (0.5, 1 or 2 x 120 mg rod containing 6mg of deslorelin). The results obtained with the dogs are set out in figures 9 to 19 and Tables 1 to 4. The results show that the formulation is able to suppress testosterone levels in dogs for 12 months or more and in bitches for at least 5 months. Accordingly, the formulation of the present invention is able to prevent reproductive function in dogs over an extended period of time.

TABLE 1
Progesterone positive bitches - non pregnant

Dogs	Implanted	Observation (after 1 month)
BA1/6	May 1996	No post treatment oestrus
BA2/6	May 1996	No post treatment oestrus
BA3/6	May 1996	No post treatment oestrus
PW1/6	May 1996	Mild oestrus display Progesterone low
PW4/12	May 1996	Progesterone dropped by treatment

Results for this group of 5 bitches demonstrate rapid suppression of reproductive function and of plasma sex hormone levels over the first few weeks post implantation.

TABLE 2
Progesterone positive bitches - pregnant

Dogs	Implanted	Observation (after 0.5 to 1 months)
BA1/61	June 1996	No oestrus
PW1/12	May 1996	No oestrus

These are controls in pregnant bitches.

TABLE 3
Progesterone positive bitches

Dogs	Implanted	Observation (after 2 to 5 months)
BB1/6	January 1996	Display of oestrus then no activity
BB2/6	February 1996	Display of oestrus then no activity
BB3/6	February 1996	Display of oestrus then no activity
BB4/6	March 1996	Display of oestrus then no activity
BB1/31	April 1996	Display of oestrus then no activity
BB1/61	April 1996	Prolonged oestrus

Results for this group of 5 bitches show that reproductive behaviour and plasma hormone levels (not shown) can be suppressed for at least 5 months following implantation.

TABLE 4
Implant Safety in dogs

Dog No.	Histology, at Implant Site	Return to Fertility (after 12 months)
Dog 46	No cellular changes detected	Yes
Dog 79	No cellular changes detected	Yes
Dog 40	No tissue taken	Yes
Dog 47	No tissue taken	Yes

These results show no negative pathological changes at the implantation site and return to fertility of 4 dogs implanted with deslorelin implants for 12 months.

CLAIMS:-

1. A pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, *in vitro*, it releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37°C at a rate of about 2-80 µg/day for at least 200 days.
2. A formulation according to claim 1, wherein, *in vitro*, the formulation releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37°C at a rate of about 2-80 µg/day for at least 300 days.
3. A formulation according to claim 1 or 2, wherein the formulation comprises about 2-10% (w/w) deslorelin (on an active basis), about 0.5-2.5% (w/w) lecithin and about 85-97.5% (w/w) stearin.
4. A method according to claim 3, wherein the formulation comprises about 5-10% (w/w) deslorelin (on an active basis), about 0.5-1.5% (w/w) lecithin and about 89-94% (w/w) stearin.
5. A formulation according to claim 3, wherein the formulation comprises about 5% (w/w) deslorelin (on an active basis), 1% (w/w) lecithin and 94% (w/w) stearin.
6. A formulation according to claim 3, wherein the formulation comprises 5% (w/w) deslorelin (on an active basis), 2% (w/w) lecithin and 93% (w/w) stearin.
7. A formulation according to any of the preceding claims, wherein the formulation is for administration to humans.
8. A formulation according to any one of claims 1 to 6, wherein the formulation is for administration to dogs and/or cats.

9. A method of preventing reproductive function in animals for at least 3 months, the method comprising administering to the animal a formulation according to any one of claims 1-8.
- 5 10. A method of treating a disease or condition for which suppression of sex hormone levels is beneficial, in an animal, the method comprising administering to the animal a formulation according to any one of claims 1 to 8.
- 10 11. A method according to claim 10, wherein the disease or condition is one wherein reduction of testosterone or estradiol levels will be beneficial.
- 15 12. A method according to claim 10 or 11, wherein the disease or condition is selected from prostate cancer, ovarian and breast cancer, endometriosis, myoma and premenstrual tension, and precocious puberty.

1 / 21




FIGURE 1

SUBSTITUTE SHEET (Rule 26)

2/21




FIGURE 2

SUBSTITUTE SHEET (Rule 26)





FIGURE 3

SUBSTITUTE SHEET (Rule 26)

4 / 21



5/21




FIGURE 5

SUBSTITUTE SHEET (RULE 26)




FIGURE 9

SUBSTITUTE SHEET (Rule 26)

7 / 21




FIGURE 7

SUBSTITUTE SHEET (Rule 26)




FIGURE 8

SUBSTITUTE SHEET (Rule 26)

9/21




FIGURE 9a

SUBSTITUTE SHEET (Rule 26)

10/21




FIGURE 9b

SUBSTITUTE SHEET (Rule 26)




FIGURE 9c

SUBSTITUTE SHEET (RULE 26)

12/21




FIGURE 9d

SUBSTITUTE SHEET (Rule 26)

13/21





FIGURE 10a

SUBSTITUTE SHEET (Rule 26)



SUBSTITUTE SHEET (Rule 26)

15/21




FIGURE 10c

SUBSTITUTE SHEET (Rule 26)




FIGURE 10d

SUBSTITUTE SHEET (Rule 26)

17 / 21




FIGURE 11a

SUBSTITUTE SHEET (Rule 26)




FIGURE 11b

SUBSTITUTE SHEET (Rule 26)

19/21




FIGURE 11c

SUBSTITUTE SHEET (Rule 26)




FIGURE 12

SUBSTITUTE SHEET (Rule 26)




FIGURE 13

SUBSTITUTE SHEET (Rule 26)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 96/00370

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: A61K 38/09

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: A61K 37/02, 37/43

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AU:IPC as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DERWENT, CA, MEDLINE: DESLORELIN

STN: SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Clinical Endocrinology and Metabolism Volume 73, No. 5, 1991 (Philadelphia, U.S.A.), LIU, Linda et al, "Effects of Pituitary-Testicular Axis Suppression in Utero and during the Early Neonatal Period with a Long-Acting Luteinizing Hormone-Releasing Hormone Analog on Genital Development, Somatic Growth, and Bone Density in Male Cynomolgus Monkeys in the First 6 Months of Life", pages 1038-1043 See especially page 1039.	1, 2, 7-12

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
4 September 1996

Date of mailing of the international search report

12 SEPT 1996

Name and mailing address of the ISA/AU
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

R.L. POOLEY

Telephone No.: (06) 283 2242

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, 92/18107, A, (UNIVERSITY OF SOUTHERN CALIFORNIA) 29 October 1992 See especially pages 7, 13	1, 2, 7-12
X	EP, 302582, A, (SOUTHERN RESEARCH INSTITUTE) 8 February 1989 See especially page 2 lines 11-26	1, 2, 7-12
X	GB, 2052258, A, (SYNTEX INC.) 28 January 1981 See especially page 1 line 38, page 2 line 41	1, 2, 7-12
A	WO, 93/15722, A, (SYNTEX INC.) 19 August 1993	
A	US, 3917825, A, (TAKEDA CHEMICAL INDUSTRIES LTD) 4 November 1975	
A	AU, 37929/78 (519687) A, (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 17 January 1980	
A	British Poultry Science, Volume 33, No.3 1992, (Edinburgh, Scotland), A.J. TILBROOK et al, "Short-term reduction in Egg Production in Laying Hens Treated with an Agonist of GnRH", pages 621-638	
P,X	Journal of Animal Science, Volume 74, No. 1, 1996 (Champaign, Illinois, U.S.A.), D'Occio, M.J. et al "Controlled Reversible Suppression of Beef Heifers and Cows using Agonists of Gonadotrophin-Releasing Hormone", pages 218-225 See especially page 233	1, 2, 7-12
P,X	Biology of Reproduction, Volume 54, No. 1, 1996 (Champaign, Illinois, U.S.A.), D'Occio, M.J. et al "Characteristics of Luteinizing Hormone (LH) and Testosterone Secretion, Pituitary Responses to LH-Releasing Hormone (LHRH), and Reproductive Function in Young Bulls Receiving the LHRH Agonist Deslorelin:Effect of castration on LH responses to LHRH", pages 45-52 See especially page 46	1, 2, 7-12

INTERNATIONAL SEARCH REPORT

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member				
WO	92/18107,A	CA	2084891,A	EP	538443,A	NO	924755,A	
		US	5211952,A	US	5340584,A	US	5340585,A	
		US	5340586,A					
EP	302582,A	AU	10992/88,A	CA	1302260,A	DE	3850823,A	
		EP	302582,A	JP	1042420,A	US	4897268,A	
GB	2052258,A	US	4256737,A					
WO	93/15722,A	US	5470582,A					
US	3917825,A	AU	61163/73,A	CA	1012062,A	DE	2350747,A	
		FR	2202678,A	GB	1393628,A	JP	49061320,A	
		US	3917825,A					
AU	37929/78,A	CA	1110232,A	DE	2830629,A	FR	2397192,A	
		SE	7807816,A	US	4218439,A			
END OF ANNEX								

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USP10)